These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6295957)

  • 21. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations.
    Cappel R
    Arch Virol; 1976; 52(1-2):29-35. PubMed ID: 187150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
    Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
    J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of monoclonal antibodies against nucleocapsid proteins of herpes simplex virus types 1 and 2.
    Zweig M; Heilman CJ; Rabin H; Hopkins RF; Neubauer RH; Hampar B
    J Virol; 1979 Nov; 32(2):676-8. PubMed ID: 91687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement-fixing antigens of herpes simplex virus types 1 and 2: reactivity of capsid, envelope, and soluble antigens.
    Martin ML; Palmer EL; Kissling RE
    Infect Immun; 1972 Feb; 5(2):248-54. PubMed ID: 4117881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral response to herpes simplex virus type 1 in latent and active infection.
    Santiago J; Gomez B
    J Infect Dis; 1988 Apr; 157(4):817-9. PubMed ID: 2831287
    [No Abstract]   [Full Text] [Related]  

  • 26. Cellular immunity and circulating antibody to herpes simplex virus in subjects with recurrent herpex simplex lesions and controls as measured by the mixed leukocyte migration inhibition test and complement fixation.
    Gange RW; de Bats A; Park JR; Bradstreet CM; Rhodes EL
    Br J Dermatol; 1975 Nov; 93(5):539-44. PubMed ID: 173386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity.
    Norrild B; Shore SL; Cromeans TL; Nahmias AJ
    Infect Immun; 1980 Apr; 28(1):38-44. PubMed ID: 6247286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of antibody in in vitro stimulation of lymphocytes.
    Kapoor AK; Khan IU; Bhushan V
    Indian J Exp Biol; 1983 Nov; 21(11):583-4. PubMed ID: 6327508
    [No Abstract]   [Full Text] [Related]  

  • 29. A 165 kd protein of the herpes simplex virion shares a common epitope with the regulatory protein, ICP4.
    Bibor-Hardy V; Sakr F
    Biochem Biophys Res Commun; 1989 Aug; 163(1):124-30. PubMed ID: 2476124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative titers of antibodies to individual polypeptide antigens of herpes simplex virus type 1 in human sera.
    Eberle R; Mou SW
    J Infect Dis; 1983 Sep; 148(3):436-44. PubMed ID: 6311910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lymphocyte proliferation and IgG production with herpesvirus antigens in solid phase.
    Ljungman P; Wahren B; Sundqvist VA
    J Virol Methods; 1985 Dec; 12(3-4):199-208. PubMed ID: 2422193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically engineered herpes simplex virus vaccines.
    Watson RJ; Enquist LW
    Prog Med Virol; 1985; 31():84-108. PubMed ID: 2982176
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune response to synthetic herpes simplex virus peptides: the feasibility of a synthetic vaccine.
    Heber-Katz E; Dietzschold B
    Curr Top Microbiol Immunol; 1986; 130():51-64. PubMed ID: 3022991
    [No Abstract]   [Full Text] [Related]  

  • 34. Cell mediated immunity to herpes simplex in man. IV. A correlation of lymphocyte stimulation and inhibition of leukocyte migration.
    Russell AS; Kaiser J; Lao VS
    J Immunol Methods; 1976; 9(3-4):273-9. PubMed ID: 175120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes simplex virus vaccines.
    Meignier B; Roizman B
    Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
    [No Abstract]   [Full Text] [Related]  

  • 36. Stimulation of peripheral blood lymphocytes by herpes simplex virus in vitro.
    Scriba M
    Infect Immun; 1974 Sep; 10(3):430-6. PubMed ID: 4372170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunity to herpes simplex virus type 2: cell-mediated immunity in latently infected guinea pigs.
    Donnenberg AD; Chaikof E; Aurelian L
    Infect Immun; 1980 Oct; 30(1):99-109. PubMed ID: 6254886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunity to herpes simplex virus type 2 (HSV-2). I. Development of virus-specific lymphoproliferative and leukocyte migration inhibition factor responses in HSV-2-infected guinea pigs.
    Donnenberg AD; Bell RB; Aurelian L
    Cell Immunol; 1980 Dec; 56(2):526-39. PubMed ID: 6258811
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs.
    Lebon P
    J Gen Virol; 1985 Dec; 66 ( Pt 12)():2781-6. PubMed ID: 2999320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.